(Q44693069)

5 December 2017

title

Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. (English)

1 reference

5 December 2017

R M Sobecks

1

1 reference

5 December 2017

L Rybicki

2

1 reference

5 December 2017

M Yurch

3

1 reference

5 December 2017

M Kalaycio

4

1 reference

5 December 2017

R Dean

5

1 reference

5 December 2017

S Andresen

6

1 reference

5 December 2017

B Pohlman

7

1 reference

5 December 2017

H Duong

8

1 reference

5 December 2017

B Bolwell

9

1 reference

5 December 2017

E Copelan

10

1 reference

5 December 2017

language of work or name

English

0 references

publication date

29 August 2011

1 reference

Bone Marrow Transplantation

5 December 2017

published in

1 reference

5 December 2017

volume

47

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

633-638

1 reference

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.167

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2011.167

1 reference

Dimensions Publication ID

5 December 2017

1044929323

0 references

1 reference